Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant effects on walking ability in chronic stroke
2025-521693-33-00Phase 2Authorised
- Sponsor
- Sinfatin
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in stroke comparing Rimonabant arm with Placebo arm (2 arms). Primary endpoints: Safety and tolerability variables and Six-minute walking test (6MWT). Planned start Aug 2026; status: authorised.
02
Drugs
rimonabant
03
Conditions
stroke
Beyond the preview
Go deeper on 2025-521693-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521693-33-00.